全文获取类型
收费全文 | 4339篇 |
免费 | 257篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 155篇 |
妇产科学 | 82篇 |
基础医学 | 647篇 |
口腔科学 | 74篇 |
临床医学 | 336篇 |
内科学 | 800篇 |
皮肤病学 | 87篇 |
神经病学 | 787篇 |
特种医学 | 128篇 |
外科学 | 284篇 |
综合类 | 32篇 |
预防医学 | 310篇 |
眼科学 | 66篇 |
药学 | 475篇 |
中国医学 | 11篇 |
肿瘤学 | 267篇 |
出版年
2024年 | 3篇 |
2023年 | 45篇 |
2022年 | 159篇 |
2021年 | 282篇 |
2020年 | 97篇 |
2019年 | 151篇 |
2018年 | 166篇 |
2017年 | 126篇 |
2016年 | 146篇 |
2015年 | 141篇 |
2014年 | 193篇 |
2013年 | 258篇 |
2012年 | 345篇 |
2011年 | 344篇 |
2010年 | 192篇 |
2009年 | 163篇 |
2008年 | 235篇 |
2007年 | 286篇 |
2006年 | 257篇 |
2005年 | 215篇 |
2004年 | 186篇 |
2003年 | 157篇 |
2002年 | 138篇 |
2001年 | 49篇 |
2000年 | 41篇 |
1999年 | 38篇 |
1998年 | 16篇 |
1997年 | 13篇 |
1996年 | 10篇 |
1995年 | 9篇 |
1994年 | 6篇 |
1993年 | 5篇 |
1992年 | 18篇 |
1991年 | 19篇 |
1990年 | 13篇 |
1989年 | 15篇 |
1988年 | 11篇 |
1987年 | 13篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1975年 | 2篇 |
1969年 | 1篇 |
1967年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有4622条查询结果,搜索用时 31 毫秒
1.
Jakub Pazdrowski Aleksandra Daczak‐Pazdrowska Adriana Polaska Joanna Ka
mierska Wojciech Barczak Mateusz Szewczyk Pawe Golusiski Zygmunt Adamski Ryszard aba Wojciech Golusiski 《Skin research and technology》2019,25(6):857-861
Radiodermatitis is one of the commonest side effects of radiotherapy. They are usually assessed by semi‐quantitative clinical scores, which are not validated and may be subject to inter‐observer variability. A few previous studies suggested that high‐frequency ultrasonography (HF‐USG) is useful in the assessment of the acute phase of radiation dermatitis in breast cancer patients. (a) To monitor skin changes by HF‐USG during the course of radiotherapy due to head and neck cancers, and (b) to determine whether there is any connection between skin sonograms and the skin scoring criteria. This prospective, observational study includes patients diagnosed with head and neck cancers, treated with radiotherapy or concomitant chemoradiation. The final analysis includes six patients. In every patient, the HF‐USG as well as dermatological assessment (target lesion score—TLS and CACE v. 4.0) were performed 4×: before, in the middle, day after, and 3 months after radiotherapy. There were significant differences between non‐irradiated skin thickness and thickness of skin with clinically obvious radiodermatitis (TLS grade 1‐4; P < .0001), as well as between irradiated, unchanged skin thickness (TLS grade 0) and thickness of skin with clinically obvious radiodermatitis (TLS grade 1‐4; P = .0002). There was no significant difference between non‐irradiated and irradiated, unchanged skin thickness (TLS grade 0; P = .9318). In four patients, we demonstrated subepidermal low echogenic band (SLEB). HF‐USG can be useful tool to noninvasive and objective assessment of skin changes during radiotherapy. 相似文献
2.
3.
4.
Paroxysmal dyskinesias (PxDs) are involuntary, episodic movements that include paroxysmal kinesigenic (PKD), paroxysmal nonkinesigenic (PNKD), and paroxysmal hypnogenic (PHD) varieties. Although most PxDs are primary (idiopathic or genetic), we found 17 of our 76 patients with PxD (22%) to have an identifiable cause for their PxD (10 men; mean age, 41.4 years). Causes included peripheral trauma (in three patients), vascular lesions (in four), central trauma (in four), kernicterus (in two), multiple sclerosis (in one), cytomegalovirus encephalitis (in one), meningovascular syphilis (in one), and migraine (in one). The latency from insult to symptom onset ranged from days (trauma) to 18 years (kernicterus), with a mean of 3 years. Nine patients had PNKD, two had PKD, five had mixed PKD/PNKD, and one had PHD. Hemidystonia was the most common expression of the paroxysmal movement disorder, present in 11 patients. Both of the patients with PKD had symptom durations of <5 minutes. Symptom duration ranged from 10 seconds to 15 days for PNKD and from 5 minutes to 45 minutes for mixed PKD/PNKD. There were no uniformly effective therapies, but anticonvulsant drugs, clonazepam, and botulinum toxin injections were the most beneficial. Awareness of the variable phenomenology and the spectrum of causes associated with secondary PxD will allow for more timely diagnosis and early intervention. 相似文献
5.
6.
7.
Dariusz Marczak Aleksandra Rapa?a Monika Bekiesińska-Figatowska 《Chirurgia narzadów ruchu i ortopedia polska》2006,71(6):473-475
Transient osteoporosis of the hip is an uncommon disorder of unclear etiology. It is often confused with other diagnosis including osteonecrosis of the femoral head. Authors describe a case of transient osteoporosis of the hip of 32 years woman. The symptoms occurred in third trimester of pregnancy. The primary symptoms were right hip pain and decreased range of motion of the right hip. In diagnostic process helpful were clinical examination, X-ray, ultrasonography, MRI and microscopic examination. As a treatment authors used walking on crutches, calcitonin and calcium preparate. After a few months remission of symptoms and normalization in accessory investigations were obtained. 相似文献
8.
Jovan P Antovic Marianne Yngen Claes-G?ran G Ostenson Aleksandra Antovic H?kan N Wallen Gun Jornesk?g Margareta Blomb?ck 《Blood coagulation & fibrinolysis》2003,14(6):551-556
We investigated thrombin activatable fibrinolysis inhibitor (TAFI) and its influence on fibrinolysis by measuring pro-TAFI activity and total TAFI antigen in 38 patients with type I diabetes mellitus (18 with and 20 without microvascular complications), as well as in 20 healthy controls. The pro-TAFI levels in the two groups of patients did not differ from those in the control group. Total TAFI antigen [i.e. pro-TAFI, TAFI and inactive carboxypeptidase U (TAFIi)] tended to decrease in both the patient groups (59.7 +/- 7.2 and 73.4 +/- 8.9% with and without microvascular complications, respectively) compared with controls (91.9 +/- 12.2%) (P = 0.12). We also assessed the overall hemostatic potential (OHP) in plasma, the clot lysis time and the overall fibrinolytic potential. The OHP was significantly higher in patients with complications compared with controls (8.9 +/- 0.9 versus 6.7 +/- 0.4; P < 0.05) and also higher in the diabetics without complications (7.8 +/- 0.6), although the latter difference did not reach statistical significance. Levels of clot lysis time and overall fibrinolytic potential were similar in the two groups of patients and the controls. The increased OHP in plasma from diabetic patients with microvascular complications indicates an imbalance of the hemostatic system towards a prothrombotic state. No signs of impaired fibrinolysis were observed in patients with diabetes. Using the OHP method for estimation of overall hemostasis, it seems that TAFI does not influence either fibrinolysis or the increased thrombotic potential observed in patients with type I diabetes mellitus. 相似文献
9.
Christopher G Goetz Stanley Fahn Pablo Martinez-Martin Werner Poewe Cristina Sampaio Glenn T Stebbins Matthew B Stern Barbara C Tilley Richard Dodel Bruno Dubois Robert Holloway Joseph Jankovic Jaime Kulisevsky Anthony E Lang Andrew Lees Sue Leurgans Peter A LeWitt David Nyenhuis C Warren Olanow Olivier Rascol Anette Schrag Jeanne A Teresi Jacobus J Van Hilten Nancy LaPelle 《Movement disorders》2007,22(1):41-47
This article presents the revision process, major innovations, and clinimetric testing program for the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (UPDRS), known as the MDS-UPDRS. The UPDRS is the most widely used scale for the clinical study of Parkinson's disease (PD). The MDS previously organized a critique of the UPDRS, which cited many strengths, but recommended revision of the scale to accommodate new advances and to resolve problematic areas. An MDS-UPDRS committee prepared the revision using the recommendations of the published critique of the scale. Subcommittees developed new material that was reviewed by the entire committee. A 1-day face-to-face committee meeting was organized to resolve areas of debate and to arrive at a working draft ready for clinimetric testing. The MDS-UPDRS retains the UPDRS structure of four parts with a total summed score, but the parts have been modified to provide a section that integrates nonmotor elements of PD: I, Nonmotor Experiences of Daily Living; II, Motor Experiences of Daily Living; III, Motor Examination; and IV, Motor Complications. All items have five response options with uniform anchors of 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Several questions in Part I and all of Part II are written as a patient/caregiver questionnaire, so that the total rater time should remain approximately 30 minutes. Detailed instructions for testing and data acquisition accompany the MDS-UPDRS in order to increase uniform usage. Multiple language editions are planned. A three-part clinimetric program will provide testing of reliability, validity, and responsiveness to interventions. Although the MDS-UPDRS will not be published until it has successfully passed clinimetric testing, explanation of the process, key changes, and clinimetric programs allow clinicians and researchers to understand and participate in the revision process. 相似文献
10.
Huntington's disease (HD) is a neurodegenerative disorder associated with expansion of CAG trinucleotide repeats in the huntingtin gene. A minimum of 36 CAG repeats is usually reported in patients with clinical features of HD; 30 to 35 repeats represent an intermediate range. Here we report a 65-year-old male with autopsy-proven HD and 29 CAG repeats. 相似文献